4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Hemogenyx Pharmaceuticals Plc (HEMO) operates in the Biotechnology industry and is headquartered in London, United Kingdom with about 16 employees. Its market capitalization is roughly £41 million. In the fiscal year ended 2025-12-31, HEMO reported £0M in revenue and (£10M) in net income.
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | £0M | £0M | £0M | £0M | — |
| Gross Profit | (£1M) | (£1M) | (£2M) | (£2M) | — |
| Operating Income (EBIT) | (£5M) | (£6M) | (£6M) | (£6M) | — |
| Net Income | (£10M) | (£6M) | (£7M) | (£4M) | — |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | £4M | £4M | £6M | £7M | — |
| Total Liabilities | £3M | £3M | £3M | £4M | — |
GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HEMO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms